Literature DB >> 7477436

Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.

E Le Poul1, N Laaris, E Doucet, A M Laporte, M Hamon, L Lanfumey.   

Abstract

Electrophysiological and autoradiographic approaches were used to assess possible changes in 5-hydroxytryptamine (serotonin) 5-HT1A receptors in the rat dorsal raphe nucleus after a subchronic treatment with fluoxetine or paroxetine, two specific serotonin reuptake inhibitors with antidepressant properties. Fluoxetine or paroxetine were injected daily (5 mg/kg, i.p.) for various time periods up to 21 days. Electrophysiological recordings performed 24 h after the last injection showed that the potency of the 5-HT1A receptor agonist, 8-OH-DPAT, to depress the firing of serotoninergic neurons in the dorsal raphe nucleus within brain stem slices was significantly reduced as early as after a 3-day treatment with either drug. The proportion of recorded neurons showing desensitization of somatodendritic 5-HT1A autoreceptors increased along the treatment from approximately 40% on the 3rd day to 60-80% on the 21st day. At no time during the treatment, was the specific binding of [3H]8-OH-DPAT (agonist radioligand) or [3H]WAY-100 635 (antagonist radioligand) to 5-HT1A receptors modified in the dorsal raphe nucleus or in other brain areas, suggesting that neither the density nor the coupling of these receptors to G-proteins were probably altered in rats injected with fluoxetine or paroxetine for up to 21 days. These results show that adaptive desensitization of somatodendritic 5-HT1A autoreceptors within the dorsal raphe nucleus can already be detected after a 3-day treatment with selective serotonin reuptake inhibitors. Rather than the desensitization per se, it may be the progressive increase in the number of serotoninergic neurons with desensitized 5-HT1A autoreceptors which plays a critical role in the (slowly developing) antidepressant action of these drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477436     DOI: 10.1007/bf00176767

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices.

Authors:  C P Vandermaelen; G K Aghajanian
Journal:  Brain Res       Date:  1983-12-19       Impact factor: 3.252

Review 3.  Neurobiological mechanisms involved in antidepressant therapies.

Authors:  M Briley; C Moret
Journal:  Clin Neuropharmacol       Date:  1993-10       Impact factor: 1.592

Review 4.  Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis.

Authors:  R W Fuller
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

5.  Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

Authors:  P L Delgado; D S Charney; L H Price; G K Aghajanian; H Landis; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1990-05

6.  Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies.

Authors:  L E Schechter; F J Bolaños; H Gozlan; L Lanfumey; S Haj-Dahmane; A M Laporte; C M Fattaccini; M Hamon
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

7.  A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression.

Authors:  J Tignol
Journal:  J Clin Psychopharmacol       Date:  1993-12       Impact factor: 3.153

8.  Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists.

Authors:  J Maj; E Moryl
Journal:  Eur Neuropsychopharmacol       Date:  1993-06       Impact factor: 4.600

Review 9.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

10.  Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine.

Authors:  T Jolas; S Haj-Dahmane; E J Kidd; X Langlois; L Lanfumey; C M Fattaccini; V Vantalon; A M Laporte; J Adrien; H Gozlan
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

View more
  56 in total

1.  Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences.

Authors:  Q Li; C Wichems; A Heils; K P Lesch; D L Murphy
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.

Authors:  Trynke R de Jong; Tommy Pattij; Jan G Veening; Marcel D Waldinger; Alexander R Cools; Berend Olivier
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

3.  Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.

Authors:  Eduardo A Pineda; Julie G Hensler; Raman Sankar; Don Shin; Teresa F Burke; Andréy M Mazarati
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity.

Authors:  C Mannoury la Cour; C Boni; N Hanoun; K P Lesch; M Hamon; L Lanfumey
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

5.  Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides.

Authors:  Maura Boldrini; Mark D Underwood; J John Mann; Victoria Arango
Journal:  J Psychiatr Res       Date:  2007-06-15       Impact factor: 4.791

Review 6.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

7.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

8.  Comorbidity between epilepsy and depression: role of hippocampal interleukin-1beta.

Authors:  Andrey M Mazarati; Eduardo Pineda; Don Shin; Delia Tio; Anna N Taylor; Raman Sankar
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

9.  Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram.

Authors:  Dania V Rossi; Teresa F Burke; Julie G Hensler
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

10.  Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy.

Authors:  Paul R Albert; Brice Le François
Journal:  Front Neurosci       Date:  2010-06-17       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.